Warning on transmissible Agents
Register now for ECA's GMP Newsletter
This guideline provides standard texts for warning statements on transmissible agents to be included, in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products. The original guideline (CPMP/BPWG/BWP/561/03) was adopted by CHMP in October 2003 and came into operation in May 2004. This revision affects only the introduction, where an update related to vCJD and an addition concerning albumin as excipient are now included.
Here you will get more information: "Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products".
Related GMP News
16.04.2025FDA Warning Letter: Unauthorised Distribution of Fecal Microbiota Transplant Products
16.04.2025Development of a Risk-based Quality System for CMC R&D Laboratories in Drug Development
03.04.2025European Pharmacopoeia Commission Adopts First General Texts on mRNA Vaccines
03.04.2025FDA Warning Letter: Unlicensed biological Product, Misbranding and many other Offences
02.04.2025FDA Warning Letter: Unauthorized Drugs and Biological Products